Current Issues

Regular Industry Development Updates, Opinions and Talking Points relating to Manufacturing, the Supply Chain and Logistics.

Sound Technology Could be the Answer for Pharmaceutical Companies Weathering the Brexit Regulatory Storm

01-Dec-2017
Sound Technology Could be the Answer for Pharmaceutical Companies Weathering the Brexit Regulatory Storm
The Brexit referendum of June 2016 seems a long time ago now, but Britain is yet to fully understand the consequences of what our exit from the European Union will mean and the ramifications it will have on our businesses and manufacturing sectors. The pharma industry is one such sector that is destined to be affected greatly. Just this summer the European Medicines Agency (EMA) and the European Commission jointly published regulatory guidance that said drugs made in Britain will be treated as imports by the EU in the event of a “hard” Brexit and that the life sciences sector will face a series of new regulatory obligations as a result.

The paper is a stark reminder of the potential disruption UK-based companies could face if Britain and the EU struggle to reach agreements on regulation of various areas in the economy. However, in reality, many issues are still up in the air after only a few rounds of negotiation talks. Yet on a practical level, the EMA has already said that the agency—currently based in London’s Docklands—should find a new home for its 900 staff in an EU country.

This issue has rightly thrust the regulation of the pharmaceutical sector in the UK into the spotlight as a key point to be negotiated in the run-up to Brexit. But with so many ‘known unknowns’ what can companies operating in the industry do to prepare? And does technology now have an even more important role to play in weathering the Brexit storm?

Industry impact
Pharmaceuticals are a hugely important industry for the UK, creating thousands of jobs and generating over 10% of the country’s gross domestic product. The industry is increasingly voicing its worries about the post-Brexit future. So much so that, the chief Executive of GlaxoSmithKline, Britain’s largest drug manufacturer employing 17,000 UK staff, warned the industry needed time to adjust to the coming disruption.

And in response to the EMA paper, the Association of the British Pharmaceutical Industry (ABPI) recently warned of a “crisis” scenario of drastically reduced access to European markets and hundreds of millions of pounds of restructuring costs unless a swift regulatory deal can be struck with Brussels.

With the EMA regulating medicine for the entire EU market—which in turn accounts for a quarter of all global pharmaceutical sales—the sheer size of the potential impact of the UK’s withdrawal is undoubtedly worrying for the sector’s businesses. The process is likely to affect every stage of drug development and commercialisation, from the earliest stages of research to pricing and distribution throughout the world.

Nevertheless, the good news is that the industry already has experience of dealing with fast-changing operating environments. Like many other sectors, the pharmaceutical industry today is changing due to increased competition and demands for efficiency, alongside the development of a myriad of international regulations and supply chain complexity.

Weathering the storm
The companies that learn to adapt to new regulations are best placed to take advantage of new market opportunities and drive business growth. So, what steps should the sector be taking now to prepare for upcoming regulatory changes?

With so many unknowns, one thing is for sure—pharma companies must continue to ensure that they remain compliant with the regulations that control the market every step of the way, whether they are EU directives or the ensuing UK rulings post-Brexit.

Failure to build-in compliance to every part of a company’s processes can have a significant impact on a business. For example, if product re-testing needs to be done, it can lead to manufacturing downtime, increased manufacturing costs, product quarantines, increased waste, and product shortages. That’s why ensuring compliance—whatever that may look like in the future—must remain a priority.

During the global financial crisis, those businesses that were able to best weather the storm brought about by international economic uncertainty were those who had the right processes and procedures in place to respond quickly to the changing nature of the markets. The issue of post-Brexit uncertainty is no different.

Technology investments
In this context, technologies such as enterprise resource planning (ERP) software can add real value to pharmaceutical companies by providing a holistic view of a company’s operations and access to real time data that ensures decisions can be made to overcome potential challenges that lie ahead.

Software can automate processes and reports to make compliance much easier and businesses more efficient and better able to adapt to change. For example, post-Brexit UK businesses will have the opportunity to open up trade with new countries around the world. In order to conduct business globally, enterprise business software enables compliance with local laws, satisfies international security measures and meets the many different local and regional documentation requirements. It can also provide manufacturers with greater traceability in their business processes. ERP offers technology that will verify and track each component in the production process and assist in any needed recall actions necessary to remain compliant in all territories.

Updating legacy systems and replacing multiple disparate solutions with one, end-to-end system provides an opportunity to create a robust framework to support the various demands of local certification and audit requirements. This can include comprehensive change logs with time and date stamp capability, business process management that can deliver approval criteria for key processes as well as support for electronic signatures and Electronic Batch Records to meet the requirements of CFR 21 part 11.

Despite the uncertainty surrounding Brexit, international business will, of course, still carry on and UK pharmaceutical businesses will be looking for growth opportunities. Agile and responsive ERP technology can help pharmaceutical businesses weather turbulent times and be equipped to grow their businesses whatever regulations are placed in their way.

The Advantages of an Automated Artwork Management Solution
1 day ago
Half of English council spending goes to a handful of suppliers, risking another Carillion-sized failure
5 days ago
The Time to Modernize Your Artwork Management is Now
5 days ago
It’s time to bin receipts: ParcelHero calls for an end to wasteful paper receipts
6 days ago
Ocado sales jump thanks to 'automation done right'
1 week ago
Preparing your employees for Industry 4.0
1 week ago
How Do Product and Shipping Labels Affect Brand Visibility?
1 week ago
How will Brexit affect the events industry?
1 week ago
100 days to Christmas - ParcelCompare says it’s never too early to start planning those presents and orders
1 week ago
It’s time to blow up your business model and switch to DTC
1 week ago
How retailers can survive the death of the high street
1 week ago
ClickSoftware Announces Recent Customer Wins, Product Updates and Industry Accolades
1 week ago
Deloitte increases its focus on AI & Marketing Technology through new acquisition
2 weeks ago
How Centralized Labeling Helps QA Departments
2 weeks ago
How IoT is Changing the Waste Water Industry
2 weeks ago
M&A can put quality compliance at risk
2 weeks ago
Chinese traders must pay fair postal charges or more British retailers will collapse
2 weeks ago
Enhance real-time visibility across your operation with a proof of delivery system
3 weeks ago
Snapfulfil publishes top five tips for winning at warehousing
3 weeks ago
Government’s no-deal Brexit advice papers ‘are the equivalent of “duck and cover” nuclear warnings’
1 month ago
Brexit and Stockpiling: What’s the answer?
1 month ago
Peak? Which peak?
1 month ago
Empowering Your Supply Chain Workforce: 3 Tips for Manufacturing Directors
1 month ago
64 per cent of manufacturers rate their shop-floor IT capabilities as just average, weak or non-existent
1 month ago
The supply chain lessons of the modern grocer
1 month ago
Time to mitigate the risk of a ‘no-deal’ Brexit?
1 month ago
App Insights: How can artificial intelligence innovate supply chain management?
1 month ago
Managing Technological Change Without any Supply Chain Disruption
1 month ago
Moody’s Blues for House of Fraser; but Website Failings are Just as Damaging
1 month ago
Artificial Intelligence: What’s Now And Next In IoT-driven Supply Chain Innovation
1 month ago
Indiana Jones and the supply chain bullwhip effect
1 month ago
How Enterprise Labeling Helps You Conquer Regulatory Challenges
1 month ago
3 Tips for Empowering Millennial Warehouse Workers
1 month ago
More robots means easier delivery - but what about the infrastructure?
2 months ago
Safety in the warehouse: Five key risk areas for 360-degree protection
2 months ago
Automotive resilience, not just airbags and crash tests, but IT too
2 months ago
New High Street panel is facing a race against a terminal diagnosis
2 months ago
Delivering the supply chain revolution
2 months ago
A market of one: the potential of the personalized supply chain
2 months ago
5 EIS rules you are probably not aware of
2 months ago
TMS: an enterprise priority
2 months ago
Labeling Solutions for Global Expansion
2 months ago
Prime Day will be a $1.6bn loss-leader creating millions more Prime members, says e-commerce expert
2 months ago
Say what? The new possibilities of voice and machine driven retail
2 months ago
‘Peak faith’ in the cloud only 12-18 months away with slump to follow, warns 6point6 Cloud Gateway
2 months ago
As you were for UK manufacturing sector, but new business growth at three month high
2 months ago
Back to IoT basics: Automating outcomes to improve customer experience
2 months ago
Investigation of the "Fast Fashion" impact
3 months ago
Redefining Rental for Materials Handling Equipment
3 months ago